Compare Crispr Therapeutics AG (CRSP) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs UnitedHealth Group Inc — how do they compare? Crispr Therapeutics AG trades at $50.78 (market cap $4.97B), while UnitedHealth Group Inc trades at $419.46 (market cap $389.68B). The key difference: UnitedHealth Group Inc is far larger — about 78.4× Crispr Therapeutics AG's market cap, and UnitedHealth Group Inc pays a 2.16% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | UNH | |
|---|---|---|
Market Cap | $4.97B | $389.68B |
Sector | Health | Health |
52-Week High | $76.78 | $431.68 |
52-Week Low | $44.34 | $237.77 |
Enterprise Value | $3.32B | $436.36B |
Dividend Yield | — | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
UnitedHealth Group (UNH) trades at $429.09, up 1.05% on the day, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.23 exceeding expectations, and a dividend of $2.32 payable in June 2026. Revenue growth remains robust, reaching $447.57B in 2025, though net margins have compressed to 2.68%.
Outlook is positive due to aging demographics and tech innovation in healthcare, but risks include regulatory scrutiny and margin pressure. Wall Street's average price target of $438.33 suggests modest upside, supported by 82.69% buy ratings. Investors should weigh solid cash flow generation against legal challenges and rising debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
